Market Access Brazil: Unlocking Pharma Potential

Date: July 22, 2011
Pages: 38
Price:
US$ 795.00
License [?]:
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M1F8C165BD2EN
Leaflet:

Download PDF Leaflet

Market Access Brazil: Unlocking Pharma Potential
With this year’s election of president Dilma Rousseff, Brazil has indicated a willingness to encourage long-term foreign investment in the pharmaceutical industry. Yet while Rousseff has set three critical path priorities to ensure investment flows into the country, there are serious concerns. Price setting, the ‘big stick’ of the compulsory licenses, burdensome tax laws, slow product approvals and linguistic barriers have all emerged as key issues. Complicating matters is competition from government-favoured generics and a high volume in illegally-traded drugs, which represent 25 percent of all pharmaceuticals sold.

Yet while those issues may seem insurmountable, gaining access to the fast-growing and potentially rich Brazilian market is not impossible—with the right information.

Report overview

Market Access Brazil: Unlocking Pharma Potential lays bare the otherwise complex operations of the Brazilian health industry. From an examination of health care responsibilities and the role of the National Health Surveillance Agency (ANVISA) to consumer trends, the latest patent protection issues, the role of generics and ongoing battle over intellectual property, the report provides clear insight into an evolving landscape. Containing interviews with experts, financial comparatives and updates from multinationals in the region, the report offers a compelling overview of Brazil’s pharmaceutical industry.

Key features
  • Breakdown of market trends and where opportunities exist
  • Examination of intellectual property and price controls and their impact on foreign pharmaceutical manufacturers
  • Role of generics, their phenomenal success and its impact on market share for the top ten producers
  • Explanation of licensing agreements, their loopholes and legislation to close them
  • Outline of investing within a protectionist environment, with a look at agreements that impact the pharma industry
  • Company updates on Pfizer, sanofi-aventis, Laboratorios Silanes de Mexico, Amgen, Hypermarcas de Brazil and GlaxoSmithKline amongst others
Key benefits
  • Clear insight into the complex and evolving regulatory landscape in Brazil
  • A roadmap to the barriers and potholes facing multinationals
  • Expert analysis of key issues facing the industry
Key questions asked
  • How is the political situation in Brazil impacting overseas investment by pharma?
  • What barriers exist to market access and how can they be overcome?
  • What are the emerging trends in intellectual property, licensing agreements and patent protection?
  • What response has been made to questions about price control?
Expert Views
  • Marin Osorio, Senior Secretary, Brazilian Ministry of Health
  • Odinir Finotti, President, Pro Genericos
  • Patrice Grand, Latin American affairs, Bristol-Myers Squibb
  • Ricardo Mendes da Silva, President, Ache Laboratorios Farmaceuticos
  • Maximilian Gorissen, Compustream Consultoria Ltda
  • Ricardo Ruiz, Adjunct Professor, Federal University of Minas Gerais
  • Emilio Wien, Health Economist, Brazilian Ministry of Health
EXECUTIVE SUMMARY

INTRODUCTION

THE BRAZILIAN PHARMACEUTICAL MARKET


Healthcare provision
Health sector responsibilities
  ANVISA
  Principal pharmaceutical patent legislation
Patent protection
  Pharmaceutical patent applications (Jan 2001-Jan 2011)
Accessing the Brazilian pharmaceutical market

TRENDS IN THE BRAZILIAN PHARMACEUTICAL MARKET

Prescription Data for Brazil, 2009/10
Pharmaceuticals in Brazil, User Profile
  Pharmaceutical Production in Brazil by Type of Capital, 2010
Intellectual Property
Generics
  Estimated Market Shares of the Top 10 Pharma Companies in Brazil, June 2011
Licensing agreements
  Measures to ensure the legality of medicines in Brazil
  Interview with Marin Osorio, Senior Secretary, Ministry of Health
Price control
  New reimbursement legislation
  Multiple trade marks
  The 'Pipeline Mechanism'
  Investing within a protectionist environment
Establishing a presence in Brazil
The Brazilian market in comparative perspective
  Pharma sector competitive infrastructure index in Latin American markets (June 2010)
  Latin American pharmaceutical market sizes: Estimates and forecasts, 2009-14
  Latin American agreements influencing Brazil's pharma industry

COMPANY UPDATES

The Brazilian pharmaceutical market: Some recent deals
Ache
Amgen
Bristol-Myers Squibb
Eurofarma
Novartis
Roche
Skip to top


Ask Your Question

Market Access Brazil: Unlocking Pharma Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: